Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies

1991 ◽  
Vol 62 (5) ◽  
pp. 156-159 ◽  
Author(s):  
A. M. Carella ◽  
E. Gaozza ◽  
A. Congiu ◽  
P. Carlier ◽  
S. Nati ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Graft Versus Host Disease ◽  
Marrow Transplantation ◽  
Hematological Malignancies ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Host Disease ◽  
Graft Versus Host ◽  
Autologous Bone

INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION

The Lancet ◽  
1989 ◽  
Vol 333 (8641) ◽  
pp. 754-757 ◽  
Author(s):  
RichardJ. Jones ◽  
AllanD. Hess ◽  
RisaB. Mann ◽  
Steven Piantadosi ◽  
GeorgiaB. Vogelsang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Graft Versus Host Disease ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Host Disease ◽  
Graft Versus Host ◽  
Autologous Bone

scholarly journals Reversal of Graft-Versus-Host Disease with Infusion of Autologous Bone Marrow

1994 ◽  
Vol 3 (2) ◽  
pp. 187-192 ◽  
Author(s):  
Camillo Ricordi ◽  
Anreas G. Tzakis ◽  
Adriana Zeevi ◽  
Witold B. Rybka ◽  
Anthony J. Demetris ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Graft Versus Host Disease ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Safety Net ◽  
Allogeneic Bone ◽  
Host Disease ◽  
Graft Versus Host ◽  
Autologous Bone

Graft-versus-host disease (GVHD) remains a major complication of bone marrow transplantation. This report describes reversal of GVHD by infusion of stored recipient bone marrow following combined liver-bone marrow allotransplantation. Graft-versus-host disease developed at the end of the first postoperative week. The skin involvement progressively spread to approximately 80% of the body surface and was not affected by modification of the immunosuppressive treatment. On the 42nd and 43rd postoperative day 1.23 × 108 and 1.6 × 108 autologous bone marrow cells per kg of recipient body weight were infused. The skin rush began to dramatically improve and resolved within 2 wk from the autologous marrow infusion. Autologous bone marrow storage previous to allogeneic bone marrow transplantation for tolerance induction could constitute a safety net in case of occurrence of GVHD.

Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.

1994 ◽  
Vol 12 (2) ◽  
pp. 249-257 ◽  
Author(s):  
M J Kennedy ◽  
G B Vogelsang ◽  
R J Jones ◽  
E R Farmer ◽  
A D Hess ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Ifn Gamma ◽  
Graft Versus Host ◽  
Historic Control ◽  
Autologous Bone

PURPOSE We investigated if interferon gamma (IFN-gamma) could augment cyclosporine (CSA)-induced graft-versus-host disease (GVHD) following autologous bone marrow transplant in women with metastatic breast cancer and defined the toxicities of this therapy. PATIENTS AND METHODS Thirty-six women with advanced breast cancer were treated with CSA 2.5 mg/kg daily for 28 days and IFN-gamma 0.025 mg/m2 subcutaneously (SC) every other day, days 7 to 28 following autologous bone marrow transplantation and monitored for induction and severity of GVHD and toxicity of therapy. RESULTS GVHD was induced in 56% of patients. The severity of GVHD was greater than in a historic control population treated with CSA alone. Stage III rash was seen in 36% of patients, compared with 3% in the historic control population. Fourteen of 36 patients required therapy with topical corticosteroids and two of 36 required systemic treatment. Only three of 31 historic controls needed topical corticosteroids and no patient was treated systemically. There was no severe visceral GVHD. Hematopoietic recovery was not delayed. There were three toxic deaths. CONCLUSION CSA-induced GVHD can be safely augmented by IFN-gamma in women treated with high-dose alkylating agents and autologous bone marrow transplantation. There is little evidence of increased toxicity. Evidence of antitumor efficacy awaits further investigation.

Sign in / Sign up

Export Citation Format

Share Document